Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew J Armstrong

Showing results (21-30 of 120) with videos related to

Pageof 12
Sort By:
The New England Journal of Medicine|September 17, 2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitisMatthew J Armstrong, Diarmaid D Houlihan, Ian A Rowe
Frontiers in Endocrinology|December 1, 2016
How Useful Are Monogenic Rodent Models for the Study of Human Non-Alcoholic Fatty Liver Disease?Jake P Mann, Robert K Semple, Matthew J Armstrong
The American Journal of Gastroenterology|September 1, 2018
Alcohol Consumption in Patients with Non-alcoholic Fatty Liver Disease: Convenient vs. Inconvenient TruthsMatthew J Armstrong, Jessica L Mellinger, Palak J Trivedi
Gastroenterology|August 8, 2017
Transplant-Free Survival Rates After Covered Transjugular Intrahepatic Portosystemic ShuntDaniel Schmidt-Martin, Matthew J Armstrong, Ian A Rowe
Current Opinion in Gastroenterology|June 17, 2009
Recent advances in coeliac diseaseMatthew J Armstrong, Gerry G Robins, Peter D Howdle
Hepatology (Baltimore, Md.)|January 4, 2012
Prioritizing treatment experienced patients with hepatitis C infection for treatment with telaprevir: a number needed to treat approachIan A Rowe, Matthew J Armstrong, Diarmaid D Houlihan
Alimentary Pharmacology & Therapeutics|November 12, 2019
Editorial: effect of exercise on physical frailty in patients with chronic liver disease. Authors' replyMatthew J Armstrong, Felicity R Williams, Jill Johnson, et al.
Human Molecular Genetics|July 27, 2019
Diverse and dynamic DNA modifications in brain and diseasesMatthew J Armstrong, Yulin Jin, Emily G Allen, et al.
Hepatology Communications|June 18, 2021
Assessment of the Frail Patient With End-Stage Liver Disease: A Practical Overview of Sarcopenia, Physical Function, and DisabilityFelicity R Williams, Don Milliken, Jennifer C Lai, et al.
Hepatology (Baltimore, Md.)|September 5, 2013
Extrahepatic complications of nonalcoholic fatty liver diseaseMatthew J Armstrong, Leon A Adams, Ali Canbay, et al.
Pageof 12

Showing results (21-30 of 120) with videos related to

Sort By:
Pageof 12
The New England Journal of Medicine|September 17, 2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitisMatthew J Armstrong, Diarmaid D Houlihan, Ian A Rowe
Frontiers in Endocrinology|December 1, 2016
How Useful Are Monogenic Rodent Models for the Study of Human Non-Alcoholic Fatty Liver Disease?Jake P Mann, Robert K Semple, Matthew J Armstrong
The American Journal of Gastroenterology|September 1, 2018
Alcohol Consumption in Patients with Non-alcoholic Fatty Liver Disease: Convenient vs. Inconvenient TruthsMatthew J Armstrong, Jessica L Mellinger, Palak J Trivedi
Gastroenterology|August 8, 2017
Transplant-Free Survival Rates After Covered Transjugular Intrahepatic Portosystemic ShuntDaniel Schmidt-Martin, Matthew J Armstrong, Ian A Rowe
Current Opinion in Gastroenterology|June 17, 2009
Recent advances in coeliac diseaseMatthew J Armstrong, Gerry G Robins, Peter D Howdle
Hepatology (Baltimore, Md.)|January 4, 2012
Prioritizing treatment experienced patients with hepatitis C infection for treatment with telaprevir: a number needed to treat approachIan A Rowe, Matthew J Armstrong, Diarmaid D Houlihan
Alimentary Pharmacology & Therapeutics|November 12, 2019
Editorial: effect of exercise on physical frailty in patients with chronic liver disease. Authors' replyMatthew J Armstrong, Felicity R Williams, Jill Johnson, et al.
Human Molecular Genetics|July 27, 2019
Diverse and dynamic DNA modifications in brain and diseasesMatthew J Armstrong, Yulin Jin, Emily G Allen, et al.
Hepatology Communications|June 18, 2021
Assessment of the Frail Patient With End-Stage Liver Disease: A Practical Overview of Sarcopenia, Physical Function, and DisabilityFelicity R Williams, Don Milliken, Jennifer C Lai, et al.
Hepatology (Baltimore, Md.)|September 5, 2013
Extrahepatic complications of nonalcoholic fatty liver diseaseMatthew J Armstrong, Leon A Adams, Ali Canbay, et al.
Pageof 12